Beacon Therapeutics Overview

  • Status
  • Private

  • Employees
  • 95

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $75.2M

  • Investors
  • 8

Beacon Therapeutics General Information

Description

Operator of a clinical-stage biotechnology company intended to treat patients with rare lung and eye diseases. The company utilizes a proprietary gene therapy platform to develop transformational genetic therapies for patients with rare and debilitating diseases, with a focus on ophthalmology, enabling clinicians to improve the lives of patients with severe conditions significantly.

Contact Information

Formerly Known As
Alliance Holdco
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rolling Stock Yard, 2nd floor
  • 188 York Way, Kings Cross
  • London N7 9AS
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Rolling Stock Yard, 2nd floor
  • 188 York Way, Kings Cross
  • London N7 9AS
  • England, United Kingdom
+44 020

Beacon Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beacon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 09-Jan-2026 $75.2M Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B) 03-Jul-2024 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A) 12-Jun-2023 $119M $119M Completed Clinical Trials - Phase 3
1. Accelerator/Incubator 01-Mar-2023 Completed Startup
To view Beacon Therapeutics’s complete valuation and funding history, request access »

Beacon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C Preferred
Series B3 Preferred
Series B2 Preferred
Series B1 Preferred
Series A Preferred
Ordinary 11,103,867 $0.000013 $1.34 $1.34 1x $1.34 4.52%
Ordinary 48,796,133 $0.000013 $1.11 $1.11 1x $1.11 19.86%
To view Beacon Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Beacon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company intended to treat patients with rare lung and eye diseases. The compa
Drug Discovery
London, United Kingdom
95 As of 2026

Paris, France
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beacon Therapeutics Competitors (3)

One of Beacon Therapeutics’s 3 competitors is SparingVision, a Venture Capital-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SparingVision Venture Capital-Backed Paris, France
GenSight Biologics Formerly VC-backed Paris, France
Coave Therapeutics Venture Capital-Backed Paris, France
You’re viewing 3 of 3 competitors. Get the full list »

Beacon Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beacon Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Goldman Sachs Asset Management Asset Manager Minority
Retinal Degeneration Fund Not-For-Profit Venture Capital Minority
Advent Life Sciences Venture Capital Minority
Forbion Venture Capital Minority
Oxford Science Enterprises Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Beacon Therapeutics Acquisitions (1)

Beacon Therapeutics’s most recent deal was a Merger/Acquisition with Applied Genetic Technologies. The deal was made on 01-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Applied Genetic Technologies 01-Dec-2022 Merger/Acquisition Drug Discovery
To view Beacon Therapeutics’s complete acquisitions history, request access »

Beacon Therapeutics FAQs

  • Where is Beacon Therapeutics headquartered?

    Beacon Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Beacon Therapeutics?

    Beacon Therapeutics has 95 total employees.

  • What industry is Beacon Therapeutics in?

    Beacon Therapeutics’s primary industry is Drug Discovery.

  • Is Beacon Therapeutics a private or public company?

    Beacon Therapeutics is a Private company.

  • What is the current valuation of Beacon Therapeutics?

    The current valuation of Beacon Therapeutics is .

  • What is Beacon Therapeutics’s current revenue?

    The current revenue for Beacon Therapeutics is .

  • How much funding has Beacon Therapeutics raised over time?

    Beacon Therapeutics has raised $362M.

  • Who are Beacon Therapeutics’s investors?

    Goldman Sachs Asset Management, Retinal Degeneration Fund, Advent Life Sciences, Forbion, and Oxford Science Enterprises are 5 of 8 investors who have invested in Beacon Therapeutics.

  • Who are Beacon Therapeutics’s competitors?

    SparingVision, GenSight Biologics, and Coave Therapeutics are competitors of Beacon Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process